TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07833618: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of ALT001 in Patients With Amyotrophic Lateral Sclerosis

Sponsor: Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07833618 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07833618 Rescue Dossier →